Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM. Papp KA, et al. Among authors: mulani pm. Clin Drug Investig. 2011;31(1):51-60. doi: 10.2165/11539360-000000000-00000. Clin Drug Investig. 2011. PMID: 20932070
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Kimball AB, et al. Among authors: mulani pm. Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21110526 Clinical Trial.
Economic burden of comorbidities in patients with psoriasis is substantial.
Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Kimball AB, et al. Among authors: mulani pm. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):157-63. doi: 10.1111/j.1468-3083.2010.03730.x. Epub 2010 Jun 17. J Eur Acad Dermatol Venereol. 2011. PMID: 20561129
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM. Leonardi C, et al. Among authors: mulani pm. Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20. Br J Dermatol. 2012. PMID: 22564148 Clinical Trial.
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM. Strober BE, et al. Among authors: mulani pm. Br J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2. Br J Dermatol. 2012. PMID: 22897348 Clinical Trial.
59 results